INVA Quote, Financials, Valuation and Earnings

Merck & Co., Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of 33.68%. Innoviva, Inc.'s return on equity of 17.06% beat Merck & Co., Inc.'s return on equity of 39.63%.

Innoviva, Inc. has a consensus price target of $32.50, signalling upside risk potential of 64.81%. On the other hand Merck & Co., Inc. has an analysts' consensus of $117.48 which suggests that it could grow by 8.86%. Given that Innoviva, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Innoviva, Inc. is more attractive than Merck & Co., Inc..

Innoviva, Inc. has a beta of 0.443, which suggesting that the stock is 55.652% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.04% to investors and pays a quarterly dividend of $0.85 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Innoviva, Inc. quarterly revenues are $111.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Innoviva, Inc.'s net income of $89.9M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Innoviva, Inc.'s price-to-earnings ratio is 14.15x while Merck & Co., Inc.'s PE ratio is 14.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 3.88x versus 4.26x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of -301.29%. Innoviva, Inc.'s return on equity of 17.06% beat Nektar Therapeutics's return on equity of -327.67%.

Innoviva, Inc. has a consensus price target of $32.50, signalling upside risk potential of 64.81%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 200.89%. Given that Nektar Therapeutics has higher upside potential than Innoviva, Inc., analysts believe Nektar Therapeutics is more attractive than Innoviva, Inc..

Innoviva, Inc. has a beta of 0.443, which suggesting that the stock is 55.652% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.624%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $111.3M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Innoviva, Inc.'s net income of $89.9M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Innoviva, Inc.'s price-to-earnings ratio is 14.15x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 3.88x versus 39.21x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Oramed Pharmaceuticals, Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of -382.1%. Innoviva, Inc.'s return on equity of 17.06% beat Oramed Pharmaceuticals, Inc.'s return on equity of 27.49%.

Innoviva, Inc. has a consensus price target of $32.50, signalling upside risk potential of 64.81%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could fall by -6.61%. Given that Innoviva, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Innoviva, Inc. is more attractive than Oramed Pharmaceuticals, Inc..

Innoviva, Inc. has a beta of 0.443, which suggesting that the stock is 55.652% less volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.511%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals, Inc. offers a yield of 7.18% to investors and pays a quarterly dividend of $0.25 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $111.3M, which are larger than Oramed Pharmaceuticals, Inc. quarterly revenues of --. Innoviva, Inc.'s net income of $89.9M is higher than Oramed Pharmaceuticals, Inc.'s net income of $48.4M. Notably, Innoviva, Inc.'s price-to-earnings ratio is 14.15x while Oramed Pharmaceuticals, Inc.'s PE ratio is 3.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 3.88x versus 72.44x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of 21.32%. Innoviva, Inc.'s return on equity of 17.06% beat Pfizer Inc.'s return on equity of 10.84%.

Innoviva, Inc. has a consensus price target of $32.50, signalling upside risk potential of 64.81%. On the other hand Pfizer Inc. has an analysts' consensus of $28.78 which suggests that it could grow by 8.61%. Given that Innoviva, Inc. has higher upside potential than Pfizer Inc., analysts believe Innoviva, Inc. is more attractive than Pfizer Inc..

Innoviva, Inc. has a beta of 0.443, which suggesting that the stock is 55.652% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.49% to investors and pays a quarterly dividend of $0.43 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $111.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Innoviva, Inc.'s net income of $89.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Innoviva, Inc.'s price-to-earnings ratio is 14.15x while Pfizer Inc.'s PE ratio is 15.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 3.88x versus 2.41x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.